Clinical trial NCT02183194: Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts
Official title: A Prospective, MultiCenter, Single-arm, Post-market Study of Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts (ACCESS)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Dysfunctional AV Graft
Dysfunctional AV Fistula
Lead sponsor: C. R. Bard
Sponsor class: INDUSTRY
First posted: 2014-07-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the Lutonix® 035 Drug Coated Balloon PTA Catheter (CE mark) for use as intended in the treatment of subjects with clinically significant hemodialysis vascular access stenosis or occlusion.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years
2. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form (ICF)
3. Hemodialysis access on the arm presenting with any clinical abnormalities as defined in the K/DOQI guidelines
4. Native AV fistula or synthetic AV graft has been implanted ≥30 days
5. Target de novo or non-stented restenotic lesion(s) consisting of a \>50% stenosis by visual estimate. Successful treatment of non target lesion(s) (residual stenosis \<30% by visual estimate) without procedural complication by standard of care
6. Successful predilatation of the target lesion with a percutaneous transluminal angioplasty (PTA) balloon
7. Intended target lesion(s) (maximum of 2) can be treated
8. No other prior surgical or vascular interventions within 2 weeks before and/or planned 30 days after the treatment

Exclusion Criteria:

1. Women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children
2. Known contraindication (including allergic reaction) or sensitivity to contrast media, ASA, clopidogrel, ticlopidine, paclitaxel (mild to severe cases), that cannot be adequately managed with pre-and post-procedure medication
3. Life expectancy \<12months
4. Scheduled for kidney transplant or peritoneal dialysis in the next 12months;
5. Thrombosed access
6. Stent in the target treatment area
7. Blood coagulative disorder, sepsis, or current AV access infection
8. Currently participating in an investigational drug, biologic, or device study, or previous enrollment in this study NOTE: Enrollment in another investigational drug, biologic, or device study during the follow- up period is not allowed

Primary outcomes:
measure: Efficacy: Primary Patency
timeFrame: 6 months
Secondary outcomes:
measure: Target Lesion Primary Patency (TLPP)
timeFrame: 12 months
measure: Access circuit primary patency
timeFrame: 6 and 12 months
measure: Abandonment of permanent access in the index extremity
timeFrame: 6 and 12 months
measure: Number of interventions required to maintain target lesion patency
timeFrame: 6 and 12 months
measure: Number of interventions, required to maintain access circuit patency
timeFrame: 6 and 12 months
measure: Major vascular complications
timeFrame: < or at 1 month
measure: Rate of device and procedure related adverse events
timeFrame: 1, 6 and 12 months
Other outcomes:
Locations:
city: Graz
country: Austria
facility: LKH-Univ. Klinikum Graz
city: Klagenfurt
country: Austria
facility: Klinikum Klagenfurt am Wörthersee
city: Koln
country: Germany
facility: Universitätsklinikum Köln AöR
city: Lubeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Study officials:
References: